All News

uricacid.jpg

ICYMI: Worldwide Trends in Hyperuricemia

Jack Cush, MD

A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates

Read Article
gout,podagra,MTP

EULAR26 Insights into Gout and Obesity

EurekAlert!

New EULAR 2026 data show continued treat-to-target ULT beats a discontinuation strategy for maintaining gout remission (79.2% vs. 62.9% flare-free), though many who stopped still stayed flare-free. A companion study links gout and rheumatoid arthritis to distinct, adverse body fat patterns tied to higher diabetes and cardiovascular risk.

Read Article
Vaccine2.jpg (keep)

EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases

Jack Cush, MD

This update includes new pandemic era evidence, recombinant zoster vaccine data, and new perspectives on vaccination in patients taking novel immunosuppressants. Five overarching principles and 10 vaccine recommendations follow.

Read Article
Eular stage

Late-Breaking Studies at EULAR 2026

MedPage Today

Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical conc

Read Article
EULAR flags

New Insights in Gout Clinical Management

EULAR – The European Alliance of Associations for Rheumatology – held its 2026 annual Congress in London, where gout was high on the agenda.

Read Article
APR video gout cover

Gout

Jack Cush, MD

Dr. Jack Cush reviews Gout in this continuing series for Advanced Practice Rheum. Review the companion slide deck here.

Read Article
healthcare workers

WSJ: Nurse Practitioner Is Now the Hottest Job in Healthcare

Jack Cush, MD

The Wall St. Journal has published a perspective on nurse practitioners (NP) and their very promising careers.

Read Article
RheumNow Podcast square

Quiz Talk (5.22.2026)

Jack Cush, MD

Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.

Read Article
CV.CP_.Heart_.pericarditis

Gout Control Lowers Cardiovascular Events

Jack Cush, MD

A large target emulation trial suggests that gout patients prescribed urate-lowering treatment who achieve a serum urate level lower than 6 mg/dL significantly lower their risk of cardiovascular events.

Read Article

Throughout Gout Campaign Month, RheumNow is bringing together internationally recognized experts to explore the Systemic Burden of Gout through Rx Updates, QD Clinic case discussions, and expert Vlogs designed for practicing rheumatologists. New educational content will release https://t.co/ZOQQuZinQd

Dr. John Cush RheumNow ( View Tweet)
Gout and ULT Withdrawal -- The GO TEST FINALE Trial Professor Noortje van Herwaarden reviews abstract OP001 at EULAR 2026 in London https://t.co/d8U1168SRn https://t.co/hP0EUrciTu

Links:

Dr. John Cush RheumNow ( View Tweet)
Extended-release febuxostat (HR091506) vs standard febuxostat in gout. 442 patients, 36 weeks. SUA <300 μmol/L at Week 36: 63.8% vs 40.7% (p<0.0001) A 23% difference on the most stringent urate target. Well tolerated and acceptable safety profile Abstr LB0008 @RheumNow https://t.co/PSrn7K5BVS

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2026 LB0008 Phase 3 RCT in China of pts with high urate (SUA) & 2 gout flares within last year (N=142), HR091506, an extended formulation release of Febuxostat to prolong response was superior to Febuxostat at WK36. Unclear if will proceed to regulatory submission @RheumNow https://t.co/9lcVEzcxc1

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
New Insights in Gout Clinical Management https://t.co/Eo63NUhaY2 https://t.co/oHZG1c1LhL

Links:

Dr. John Cush RheumNow ( View Tweet)
Weight management should be discussed!! Obesity management will help rheumatic diseases. EULAR guidelines below. No ACR ones exist. Best evidence in OA and Gout. #EULAR2026 plenary @RheumNow https://t.co/hBu4YeXZbu

Links:

Bella Mehta bella_mehta ( View Tweet)
ULT de-escalation in Gout: shall we do it? Short answer: No RCT 309 pts 24 mo Primary outcome remission last 6 mo 79.2% ULT continuation vs 62.9% discontinuation p=0.002 Flare incidence 12% vs 32% More NSAID/colchicine use after stopping ULT Stopping ULT = urate rises quickly & https://t.co/bYKr5axu46

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Which of the following is NOT a complication of Gout?

Dr. John Cush RheumNow ( View Tweet)

Meet the RheumNow #EULAR2026 Reporting Team Delivering real-time insights from the forefront of rheumatology: 🩺 Dr. Antoni Chan (@synovialjoints) 🩺 Dr. Mrinalini Dey (@DrMiniDey) 🩺 Dr. Jiha Lee (@JihaRheum) 🩺 Dr. Aurelie Najm (@AurelieRheumo) 🩺 Dr. Janet Pope https://t.co/zpIeGWpL6P
Dr. John Cush RheumNow ( View Tweet)
Dr. Robert Terkeltaub walks through the evolution of gout at #RheumNowLive 2026. 🎧 Listen here: https://t.co/S6RXQo2Umt #Gout #Rheumatology #MedEd https://t.co/XDbTmj3MOw

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout Control Lowers Cardiovascular Events A large target emulation trial suggests that gout patients prescribed urate-lowering treatment who achieve a serum urate level lower than 6 mg/dL significantly lower their risk of cardiovascular events. https://t.co/LcBg7yCw4c https://t.co/dBYdnq9XLJ

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×